The Shifting Geography of Early-Phase Clinical Trials
Published August 2026 — Data published in mid-2026 show China approaching the United States in total clinical trial starts and surpassing it in Phase I, prompting a federal response aimed at keeping early clinical research in the U.S.
The U.S. Lead in Early Research Has Narrowed
For most of the modern era of drug development, the United States hosted the largest share of the world's clinical trials. Analyses released in June and July 2026 show how much that position has changed, particularly in first-in-human and other Phase I studies.
This brief summarizes the figures cited in a June 2026 industry index and in testimony to the House Energy and Commerce Committee in July 2026, and considers what the trend means for U.S. sites.
Key Findings
Reagan-Udall Foundation data cited in a June 2026 industry release put the U.S. at 35% of global clinical trial starts in 2025 and China at 32%.
The same data show China's share of global clinical trial starts rising from 1% in 2009 to 32% in 2025.
Testimony to the House Energy and Commerce Committee in July 2026 reported that China accounted for 35% of Phase I trial starts by country in 2025, against 27% for the U.S. China passed the U.S. on this measure in 2021.
The same testimony noted that China accounted for 89% of Phase I trial country uses by Chinese companies in 2025, indicating that much of the growth comes from domestic sponsors.
Understanding the Shift
The headline numbers describe a real change, but they need to be read with care.
Measures Differ Between Sources
Some analyses count all trial starts, others count Phase I only, and others count the countries used by each trial. The exact percentages vary accordingly. The direction is the same in each: the U.S. share has fallen and China's has risen.
Much of the Growth Is Domestic
The 89% figure suggests that China's Phase I growth largely reflects Chinese companies running early studies at home, more than Western sponsors moving trials there. The competitive question for U.S. sites is whether that domestic capacity begins to attract global programs.
Speed of Start-Up Is the Recurring Explanation
Commentary around these figures repeatedly identifies the time needed to begin a first-in-human study as the main U.S. disadvantage. That connects this trend directly to site activation performance.
A Federal Response Is Under Way
In mid-June 2026, HHS launched Operation TrialBlazer as a pilot program, grouping initiatives intended to speed development from the IND stage through late-stage trials and to keep early clinical research in the United States.
Implications for Sites and Sponsors
For U.S. sites, the trend raises the value of the things they can control.
If sponsors choose locations partly on time to first patient, activation timelines become a competitive factor for the country as well as for each site.
Sites with dedicated early-phase capacity, intensive monitoring, and rapid safety review are the ones positioned to benefit from efforts to retain first-in-human work in the U.S.
TrialBlazer and related FDA guidance are likely to change early-phase protocol design and review. Sites should track these measures as they move from pilot to practice.
Conclusions
The United States remains the largest single location for clinical trials by most measures, but its margin has narrowed sharply and it has lost the lead in Phase I. The policy response in 2026 shows that this is now treated as a national concern.
The figures summarized here come from advocacy and industry analyses and from congressional testimony, and they use differing definitions. They are best read as evidence of direction. For sites, the practical response is the same in any case: shorter start-up and dependable early-phase execution.
This brief summarizes published industry research. Figures are reported as stated in the sources below and have not been independently verified by Clinitiative.
Discuss These Findings with Our Team
Talk with us about what this research means for your protocol, site selection, or enrollment plan.